Second-quarter revenue for the Genetics business increased 7 percent to $78.5 million from $73.7 million. This growth was driven in part by the continuing demand for prenatal screening for genetic conditions. Additionally, Genzyme experienced increased demand for its KRAS mutation testing for colorectal cancer, as recent studies have shown that identifying KRAS mutations can assist oncologists in selecting treatment for patients with colorectal cancer. This increasing recognition of the value of diagnostics in personalized medicine will continue to fuel organic growth in the Genetics business.
Oncology revenue rose in the second quarter to $33.3 million from $17.4
million based on increasing sales of Clolar and Campath(R) (alemtuzumab).
The increase also reflects the addition of European sales of Clolar, which
Genzyme began recording following its acquisition of Bioenvision Inc. late
last year. Genzyme is working to introduce Clolar worldwide as well as
expand its indications. The product is currently approved in the United
States and Europe as a third-line treatment for pediatric patients with
acute lymphoblastic leukemia. Genzyme is developing Clolar for use globally
as a first-line therapy for adult AML and myelodysplastic syndromes,
significantly larger indications that the company estimates will drive peak
annual sales of the product to approximately $600 million. Last month,
Genzyme reported encouraging results from its pivotal CLASSIC II trial
evaluating the use of Clolar to treat older adult patients with acute
myeloid leukemia. Oncology revenue also reflects growing first-line use of
Campath in the treatment of patients with B-cell chronic l
|SOURCE Genzyme Corporation|
Copyright©2008 PR Newswire.
All rights reserved